Scleroderma lung study (SLS): Differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

Annals of the Rheumatic Diseases

Volumn 66, Issue 12, 2007, Pages 1641-1647

  Clements, Philip J ^a,b   Roth, Michael D ^b   Elashoff, Robert ^b   Tashkin, Donald P ^b   Goldin, Jonathan ^b   Silver, Richard M ^c   Sterz, Mildred ^b   Seibold, James R ^d   Schraufnagel, Dean ^e   Simms, Robert W ^f   Bolster, Marcy ^g   Wise, Robert A ^h   Steen, Virginia ^i,j   Mayes, M D ^a   Connelly, Kari ^k   Metersky, Mark ^l   Furst, Daniel E ^b  

^a UCLA ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PLACEBO; PREDNISONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FUNCTIONAL STATUS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SYSTEMIC SCLEROSIS;

ADULT; BRONCHOALVEOLAR LAVAGE; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 36749001145     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.069518     Document Type: Article

References (29)

1. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
2. Clements PJ, Medsger TA Jr. Cutaneous involvement. In Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins, 2004:129-50.
3. Steen VO, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437- 44.
4. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
5. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
6. Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 2003;15:748-55.
7. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
8. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-35.
9. Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Conlorti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002;29:731-6.
10. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Eng J Med 2006;354:2655-66.
11. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh MJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962- 70.
12. Mahler DA, Weinberg DH, Wells CK, Feinstein AR. The measurement of dyspnea: contents, interobserver agreement and physiologic correlates of two new clinical indexes. Chest 1984;85:751-8.
13. American Thoracic Society. Standardization of spirometry - 1994 update. Am Rev Respir Dis 1995;152:1107-36.
14. American Association for Respiratory Care. Respir Care 1994;39:1184-90.
15. British Thoracic Society. Guidelines for the measurement of respiratory function: recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994;88:165-94.
16. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations lor a standard technique - 1995 update. Am J Respir Crit Care Med 1995;152:2185-98.
17. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696- 702.
18. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
19. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir 1982;18:419-29.
20. Crapo RO, Morris AH. Standardized single breath normal values of carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-9.
21. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 1991;144:1202-18.
22. Clements PJ, Goldin JG, Kleerup EG, Furst DE, Elashoff RM, Tashkin DP, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography in dyspnea patients with systemic sclerosis (scleroderma). Arthritis Rheum 2004;50:1909-17.
23. Goldin J, Lynch D, Strollo D, Strange C, Silver R, Clements P, et al. High resolution CT findings in scleroderma-related lung diseases. Proceedings of ATS, 2006;3, A105.
24. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997;40:1984-91.
25. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
26. Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990;98:75-83.
27. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statist Med. In press..
28. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
29. Le Guem V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004;43:1129-37.